- Zacks Small Cap Research•7 days agoAralez Pharmaceuticals (NASDAQ:ARLZ): Third Times a Charm! FDA Approves YOSPRALA®; Will Launch the First Week of October 2016
On September 15, 2016, Aralez Pharmaceuticals, Inc. (ARLZ) announced that the Food and Drug Administration (FDA) approved YOSPRALA® for patients who require aspirin for secondary prevention of cardiovascular and cerebrovascular events and who are at risk of developing aspirin associated gastric ulcers. YOSPRALA® is composed of a delayed-release aspirin (either 81 mg or 325 mg) and an immediate-release omeprazole (40 mg) intended for the secondary prevention of heart attack and stroke. For patients who have suffered a heart attack or stroke, taking daily aspirin has been shown to help prevent the occurrence a second heart attack or stroke.
- TheStreet.com•10 days ago
Aralez Pharmaceuticals (ARLZ) said on Thursday that its Yosprala drug for prevention of cardiovascular disease was approved by the FDA.
Aralez Pharmaceuticals Inc. (ARZ.TO)
Toronto - Toronto Delayed Price. Currency in CAD
|Day's Range||6.51 - 7.08|
|52wk Range||4.07 - 8.75|
|1y Target Est||N/A|
|P/E Ratio (ttm)||-4.11|
|Avg Vol (3m)||23,100|
|Dividend & Yield||N/A (N/A)|